Screening for placenta accreta at 11-14 weeks of gestation.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 21907956.
- Also identified by DOI 10.1016/j.ajog.2011.07.021.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We sought to describe the potential value of 11-14 weeks' screening for placenta accreta (PA). Patients with a history of lower segment cesarean section were prospectively included between 11-13+6 weeks over a 1.5-year period. The first 258 were offered standard screening whereas the following 105 underwent screening for PA. Women were considered high-risk when the trophoblast overlapped the scar visualized by transvaginal ultrasound and low-risk otherwise. The group screened for PA did not differ from the nonscreened group for demographic characteristics. In all, 6 of 105 (5.8%) women were considered high-risk. In the nonscreened group, 1 case of PA was discovered during an elective repeat cesarean. In the screened population, 1 case of PA occurred in a high-risk patient allowing a conservative planned management at 35 weeks. At 11-14 weeks, ultrasound may help risk stratification for PA with a specific follow-up. Early recognition of patients at risk might improve the perinatal outcome of PA.
Medical subject headings
- Placenta Accreta
- Pregnancy Trimester, First
- Ultrasonography, Prenatal